Cryoprecipitate for the correction of coagulopathy associated with liver disease

Research output: Contribution to journalArticleResearchpeer-review

Abstract

In patients with liver disease at risk of pulmonary oedema, cryoprecipitate (small volume) might be a viable alternative to fresh frozen plasma (FFP, large volume) in the correction of coagulopathy. However, the efficacy of cryoprecipitate in these patients has not been tested. We evaluated the role of cryoprecipitate in the correction of the coagulopathy of liver disease. To establish initial evidence of efficacy, six consecutive patients with hepatic failure and coagulopathy received five units of cryoprecipitate. Then, using a crossover design, 11 consecutive patients were randomized to receive either four units of FFP or five units of cryoprecipitate. Pre and post infusion International Normalized Ratio (INR), activated Partial Thromboplastin Time (aPTT), fibrinogen D-dimers, Factors V and IX, and reptilase time were measured. In the first six patients, cryoprecipitate improved the INR, aPTT and fibrinogen concentration (P=0.03). In the crossover study, FFP administration produced a greater improvement in INR (P=0.007) and aPTT (P=0.005) than cryoprecipitate. However, there were no differences in any of the other measured variables. One patient developed acute pulmonary oedema while receiving FFP. Cryoprecipitate improves the coagulopathy of liver disease. Four units of FFP are more efficacious than five units of cryoprecipitate. Cryoprecipitate may have a role in correction of the coagulopathy associated with liver disease where concerns about pulmonary oedema exist.

Original languageEnglish
Pages (from-to)357-361
Number of pages5
JournalAnaesthesia and intensive care
Volume31
Issue number4
Publication statusPublished - 1 Aug 2003
Externally publishedYes

Keywords

  • Blood: component, transfusion
  • Coagulation: protein disorders
  • Cryoprecipitate: coagulum

Cite this

@article{89f16e55b5b545ddb38727aface160a3,
title = "Cryoprecipitate for the correction of coagulopathy associated with liver disease",
abstract = "In patients with liver disease at risk of pulmonary oedema, cryoprecipitate (small volume) might be a viable alternative to fresh frozen plasma (FFP, large volume) in the correction of coagulopathy. However, the efficacy of cryoprecipitate in these patients has not been tested. We evaluated the role of cryoprecipitate in the correction of the coagulopathy of liver disease. To establish initial evidence of efficacy, six consecutive patients with hepatic failure and coagulopathy received five units of cryoprecipitate. Then, using a crossover design, 11 consecutive patients were randomized to receive either four units of FFP or five units of cryoprecipitate. Pre and post infusion International Normalized Ratio (INR), activated Partial Thromboplastin Time (aPTT), fibrinogen D-dimers, Factors V and IX, and reptilase time were measured. In the first six patients, cryoprecipitate improved the INR, aPTT and fibrinogen concentration (P=0.03). In the crossover study, FFP administration produced a greater improvement in INR (P=0.007) and aPTT (P=0.005) than cryoprecipitate. However, there were no differences in any of the other measured variables. One patient developed acute pulmonary oedema while receiving FFP. Cryoprecipitate improves the coagulopathy of liver disease. Four units of FFP are more efficacious than five units of cryoprecipitate. Cryoprecipitate may have a role in correction of the coagulopathy associated with liver disease where concerns about pulmonary oedema exist.",
keywords = "Blood: component, transfusion, Coagulation: protein disorders, Cryoprecipitate: coagulum",
author = "French, {C. J.} and R. Bellomo and P. Angus",
year = "2003",
month = "8",
day = "1",
language = "English",
volume = "31",
pages = "357--361",
journal = "Anaesthesia and intensive care",
issn = "0310-057X",
publisher = "Australian Society of Anaesthetists",
number = "4",

}

Cryoprecipitate for the correction of coagulopathy associated with liver disease. / French, C. J.; Bellomo, R.; Angus, P.

In: Anaesthesia and intensive care, Vol. 31, No. 4, 01.08.2003, p. 357-361.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Cryoprecipitate for the correction of coagulopathy associated with liver disease

AU - French, C. J.

AU - Bellomo, R.

AU - Angus, P.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - In patients with liver disease at risk of pulmonary oedema, cryoprecipitate (small volume) might be a viable alternative to fresh frozen plasma (FFP, large volume) in the correction of coagulopathy. However, the efficacy of cryoprecipitate in these patients has not been tested. We evaluated the role of cryoprecipitate in the correction of the coagulopathy of liver disease. To establish initial evidence of efficacy, six consecutive patients with hepatic failure and coagulopathy received five units of cryoprecipitate. Then, using a crossover design, 11 consecutive patients were randomized to receive either four units of FFP or five units of cryoprecipitate. Pre and post infusion International Normalized Ratio (INR), activated Partial Thromboplastin Time (aPTT), fibrinogen D-dimers, Factors V and IX, and reptilase time were measured. In the first six patients, cryoprecipitate improved the INR, aPTT and fibrinogen concentration (P=0.03). In the crossover study, FFP administration produced a greater improvement in INR (P=0.007) and aPTT (P=0.005) than cryoprecipitate. However, there were no differences in any of the other measured variables. One patient developed acute pulmonary oedema while receiving FFP. Cryoprecipitate improves the coagulopathy of liver disease. Four units of FFP are more efficacious than five units of cryoprecipitate. Cryoprecipitate may have a role in correction of the coagulopathy associated with liver disease where concerns about pulmonary oedema exist.

AB - In patients with liver disease at risk of pulmonary oedema, cryoprecipitate (small volume) might be a viable alternative to fresh frozen plasma (FFP, large volume) in the correction of coagulopathy. However, the efficacy of cryoprecipitate in these patients has not been tested. We evaluated the role of cryoprecipitate in the correction of the coagulopathy of liver disease. To establish initial evidence of efficacy, six consecutive patients with hepatic failure and coagulopathy received five units of cryoprecipitate. Then, using a crossover design, 11 consecutive patients were randomized to receive either four units of FFP or five units of cryoprecipitate. Pre and post infusion International Normalized Ratio (INR), activated Partial Thromboplastin Time (aPTT), fibrinogen D-dimers, Factors V and IX, and reptilase time were measured. In the first six patients, cryoprecipitate improved the INR, aPTT and fibrinogen concentration (P=0.03). In the crossover study, FFP administration produced a greater improvement in INR (P=0.007) and aPTT (P=0.005) than cryoprecipitate. However, there were no differences in any of the other measured variables. One patient developed acute pulmonary oedema while receiving FFP. Cryoprecipitate improves the coagulopathy of liver disease. Four units of FFP are more efficacious than five units of cryoprecipitate. Cryoprecipitate may have a role in correction of the coagulopathy associated with liver disease where concerns about pulmonary oedema exist.

KW - Blood: component, transfusion

KW - Coagulation: protein disorders

KW - Cryoprecipitate: coagulum

UR - http://www.scopus.com/inward/record.url?scp=0042424534&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 357

EP - 361

JO - Anaesthesia and intensive care

JF - Anaesthesia and intensive care

SN - 0310-057X

IS - 4

ER -